Search results for "Dydrogesterone"

showing 5 items of 5 documents

Menopause and diabetes: EMAS clinical guide

2018

Abstract Introduction Whether menopause increases the risk of type 2 diabetes mellitus (T2DM) independently of ageing has been a matter of debate. Controversy also exists about the benefits and risks of menopausal hormone therapy (MHT) in women with T2DM. Aims To summarise the evidence on 1) the effect of menopause on metabolic parameters and the risk of T2DM, 2) the effect of T2DM on age at menopause, 3) the effect of MHT on the risk of T2DM, and 4) the management of postmenopausal women with T2DM. Materials and methods Literature review and consensus of experts’ opinions. Results and conclusion Metabolic changes during the menopausal transition include an increase in and the central redis…

ESTROGEN REPLACEMENTmedicine.medical_specialtyHORMONE-REPLACEMENT THERAPYendocrine system diseasesmedicine.medical_treatment030209 endocrinology & metabolismDiseaseDydrogesteroneGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicine3123 Gynaecology and paediatricsRisk FactorsInternal medicineDiabetes mellitusType 2 diabetes mellitusDiabetes MellitusmedicineHumansNATURAL MENOPAUSEMenopausal hormone therapy; Menopause; Type 2 diabetes mellitus; Estrogen Replacement Therapy; Female; Humans; Incidence; Risk Factors; Diabetes Mellitus Type 2; MenopauseESTRADIOLMETABOLIC SYNDROME030219 obstetrics & reproductive medicineProgestogenINSULIN SENSITIVITYbusiness.industryIncidenceEstrogen Replacement TherapyENERGY-EXPENDITUREnutritional and metabolic diseasesObstetrics and GynecologyType 2 Diabetes MellitusHormone replacement therapy (menopause)medicine.disease3. Good healthMenopausePOSTMENOPAUSAL WOMENDiabetes Mellitus Type 23121 General medicine internal medicine and other clinical medicineRISK-FACTORSFemaleHEALTHMenopauseMetabolic syndromebusinessType 2Menopausal hormone therapymedicine.drug
researchProduct

Dydrogesterone use during pregnancy: Overview of birth defects reported since 1977

2009

Between 1977 and 2005, 28 cases of potential links between maternal dydrogesterone use during pregnancy and congenital birth defects were reported. The types of defects were very diverse, with no evidence of a pattern of abnormalities. The data do not provide evidence for congenital malformations associated with dydrogesterone use.

Gynecologymedicine.medical_specialtyPregnancyProgestogenObstetricsbusiness.industrymedicine.medical_treatmentAbnormalities Drug-InducedObstetrics and GynecologyCongenital malformationsDydrogesteronemedicine.diseaseMaternal ExposurePregnancyPediatrics Perinatology and Child HealthDydrogesteronemedicineAdverse Drug Reaction Reporting SystemsHumansGestationFemaleProgestinsbusinessmedicine.drugEarly Human Development
researchProduct

Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.

2003

Objective To compare the long-term effects of oral and transdermal hormone replacement therapy (HRT) on serum homocysteine levels in postmenopausal women. Design An open, prospective, controlled study. Seventy-five healthy postmenopausal women were recruited as eligible for the study. Fifty women seeking HRT were randomized to receive continuous 17beta-estradiol, either by oral (2 mg daily; n = 25) or transdermal (50 microg daily; n = 25) administration, plus 10 mg dydrogesterone daily for 14 days of each 28-day cycle. Twenty-five women unwilling to receive hormone treatment received only calcium supplementation, representing the control group. Fasting blood samples were analyzed at baselin…

Oralmedicine.medical_specialtyAdministration CutaneouHomocysteineEstronemedicine.medical_treatmentHRTAdministration OralEstroneDydrogesteroneAdministration CutaneousGastroenterologylaw.inventionchemistry.chemical_compoundFollicle-stimulating hormoneRandomized controlled triallawReference ValuesInternal medicineMedicineHumansReference ValueProspective StudiesProspective cohort studyHomocysteineTransdermalEstradiolProgesterone Congenersbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyHormone replacement therapy (menopause)Progesterone CongenerMiddle AgedHomocysteine; HRT; TransdermalPostmenopauseProspective StudieEndocrinologychemistryDydrogesteroneDrug Therapy CombinationFemaleFollicle Stimulating HormonebusinessTransdermalmedicine.drugHumanMenopause (New York, N.Y.)
researchProduct

Resolution of mixtures of steroidal hormones with micellar eluents of sodium dodecyl sulphate and acetonitrile or pentanol

2000

An optimization strategy was applied to explore the capability of hybrid micellar eluents of sodium dodecyl sulphate (SDS), using acetonitrile or pentanol as modifiers, to resolve mixtures of eleven steroids showing a wide range of hydrophobicity (clostebol acetate, dehydrotestosterone, dydrogesterone, medroxyprogesterone, medroxyprogesterone acetate, methandienone, methyltestosterone, progesterone, testosterone, testosterone enanthate and testosterone propionate). The accurate prediction of the retention behaviour of the steroids, with relative errors in the 0.8–1.7% and 0.4–2.9% ranges for SDS-acetonitrile and SDS-pentanol eluents, respectively, demonstrated the reliability of the methodo…

Testosterone propionateChromatographyChemistryElutionMedroxyprogesteronemedicine.medical_treatmentOrganic ChemistryClinical BiochemistryDydrogesteroneBiochemistryHigh-performance liquid chromatographyAnalytical ChemistrySteroidchemistry.chemical_compoundCLOSTEBOL ACETATEmedicineMethyltestosteronemedicine.drug
researchProduct

Menopause symptom management in women with dyslipidemias: An EMAS clinical guide.

2020

Abstract Introduction Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile, with an increase in the concentrations of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), apolipoprotein B (apoB) and potentially lipoprotein (a) [Lp(a)], and a decrease in the concentration of high-density lipoprotein cholesterol (HDL-C). Aim The aim of this clinical guide is to provide an evidence-based approach to management of menopausal symptoms and dyslipidemia in postmenopausal women. The guide evaluates the effects on the lipid profile both of menopausal hormone therapy an…

medicine.medical_specialtyTiboloneDydrogesteroneGeneral Biochemistry Genetics and Molecular BiologyVaginal estrogen03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOspemifeneInternal medicinemedicineHumansMass Screening030212 general & internal medicineDyslipidemias030219 obstetrics & reproductive medicinemedicine.diagnostic_testbusiness.industryHypertriglyceridemiaObstetrics and Gynecologymedicine.diseaseLipidsMenopauseEndocrinologychemistrylipids (amino acids peptides and proteins)FemaleMenopauseLipid profilebusinessDyslipidemiamedicine.drugMaturitas
researchProduct